Document is current
Any future updates will be listed below
-
Authors
Sundararajan, Vignesh https://orcid.org/0000-0002-3982-3026
Ziyu, Fang
Elfar, Gamal Ahmed
Tan, Tuan Zea https://orcid.org/0000-0001-6624-1593
Kuay, Kuee Theng
Tan, Agnes
Lai, Clemence
Wengner, Antje Margret
Hung, Huynh The
Qi, Maili
Chay, Wen Yee
Cheok, Chit Fang
Tan, David Shao Peng https://orcid.org/0000-0001-9087-5262
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (CSASI21jun-0003)
National University Cancer Institute, Singapore (NR22NMR112OM)
- License Information
-
More Information
Article History
Received: 17 July 2025
Revised: 20 April 2026
Accepted: 20 May 2026
First Online: 11 June 2026
Competing interests
: DSPT received research funding from AstraZeneca, Bayer, and Karyopharm and honoraria from AstraZeneca, MSD, Tessa Therapeutics, Novartis, Bayer, and Genmab. AMW was a permanent employee of BAYER AG at the time when the studies were performed.
: Statement for animal work: All in vivo xenograft studies adhered and performed in accordance to the SingHealth Animal Care and Use Committee (IACUC:2018/SHS/1356) guidelines on animal use and handling. The approval has been obtained from the committee and all methods were performed in accordance with the relevant guidelines and regulations. Statement for patient material: Usage of patient-derived materials has been approved by the National Health Group Domain Specific Review Board (DSRB), Reference: 2013/00705. Written informed consent was obtained from each patient. All methods were performed in accordance with the relevant guidelines and regulations.
